This trial was designed to assess the safety, tolerability and preliminary efficacy of Optisomal encapsulated Alocrest. Preliminary results show that Alocrest was generally well tolerated with acceptable and predictable toxicities and had a maximum tolerated dose comparable to that of un-encapsulated vinorelbine. In this first human study of Alocrest, the drug produced a disease control rate of 46% across a broad range of doses and tumor types.